March 28th 2023
There are currently no FDA approved therapies in this treatment setting.
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
04/29/2023
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire ®: Addressing the Top 10 Clinical Challenges in Melanoma
View More
Medical Crossfire®: How the Experts Differentiate Secondary Immunodeficiencies to Improve Patient Outcomes Across Hematologic Cancer Care
View More
Medical Crossfire®: How the Experts Differentiate Secondary Immunodeficiencies to Improve Patient Outcomes Across Hematologic Cancer Care
View More
Burst CME™: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Virtual Case Studies in Pustular Psoriasis: Refining Our Approaches to the Assessment of Our Patients
View More
Medical Crossfire®: How the Experts Differentiate Secondary Immunodeficiencies to Improve Patient Outcomes Across Hematologic Cancer Care
View More
Medical Crossfire®: How the Experts Differentiate Secondary Immunodeficiencies to Improve Patient Outcomes Across Hematologic Cancer Care
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Harnessing the Immune System to Fight Basal Cell Carcinoma: What are the Risks?
January 4th 2023In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.